Movie To Watch With 10 Year Old Boy

[Aleshia Ducharme]

To come up with this list, BioSpace identified companies that launched between September 2022 and September 2023 with Series A funding. They were then assessed using several different criteria including finance, partnerships, pipeline, growth potential and innovation. After awarding points for each category, the BioSpace editorial team ranked its top 30.

Notable: In August 2023, Apogee dosed the first participants in a Phase I trial of lead candidate APG777, which is being developed to treat atopic dermatitis and other inflammatory diseases. APG777 is also in preclinical development for asthma.

Differentiator: CARGO already has data in hand from a Phase I trial showing that treatment with CRG-022 led to durable complete responses in greater than 50% of LBCL patients in this population.

Differentiator: In addition to NIDO-361, Nido is leveraging a functional genomics discovery platform based on human cell lines that uses tailored screens to identify novel therapeutic targets for myriad neuromuscular and neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal disorders (FTD).

Notable: The past three years have made clear the potential of RNA, but the aptly named ReNAgade Therapeutics wants to push the envelope and deliver RNA medicines to previously inaccessible tissues and cells.

Differentiator: Experience. ReNAgade CEO Amit Munshi was most recently the head of Arena Pharmaceuticals, which under his stewardship grew from a $300 million company into a late clinical-stage firm with nearly 40 programs before being acquired by Pfizer for $6.7 billion. Munshi is joined by CSO Peter Smith, whose resume includes leadership roles at Alnylam and Moderna.

Differentiator: Orbital is building what it calls a first-in-kind platform that combines existing and novel RNA technologies and delivery mechanisms. And it would seem the company has the cash and experience to do it.

Differentiator: Microbubbles. Whereas traditional approaches use viral vectors to deliver a therapeutic gene, SonoThera houses its payload in a microbubble, which is then injected into the bloodstream. The microbubble is guided to the target site using an FDA-cleared ultrasound device and a proprietary acoustic profile. This approach could allow the company to avoid the immunogenicity and high costs associated with viral vectors.

Notable: The cardiovascular space experienced a resurgence in 2023, including the $145 million in Series A funds dropped into the coffers of Bitterroot Bio, a startup focused on the subspecialty of cardio-immunology.

Differentiator: Convergent claims that its lead candidate in targeting prostate cancer, CONV01-α, is different from other radioactive medicines. Using the radionuclide 225Ac, the alpha particles can deliver radiation over short distances and reduce exposure to healthier tissues and cells nearby, according to the company. In a Phase I trial of the candidate, 44% of patients with metastatic castration-resistant prostate cancer experienced a decline of prostate-specific antigen levels by more than 50% after a single dose.

Notable: Backed by Bristol Myers Squibb, Lux Capital and The Column Group, Cajal Neurosciences plans to combine human genetics and multi-omics, whole brain imaging and functional genomics to find potential drug targets.

Differentiator: Its Advanced Covalent Exploration platform uses several tools such as chemoproteomics to identify new covalent binders to disease-causing proteins as well as machine learning to find targets and build out its library of covalent compounds.

Differentiator: Juvena uses artificial intelligence to look for proteins secreted by regenerative stem cells. It plans to use the identified proteins as drug agents and develop biologics that can target their pathways as well.

Notable: Backed by several investment firms, including Mubadala Capital, Alexandra Venture Investments and Catalio Capital, among others, Georgiamune already has already picked up FDA clearance for an IND for one of its candidates, a dual-function monoclonal antibody called GIM-122 to fight cancer.

Notable: Nested is focused on discovering and developing precision therapies to treat cancer and has received backing from prominent financial names such as Goldman Sachs Asset Management and Cowan Healthcare Investments.

Differentiator: Crossbow says that its development process starts with finding a target and then uses TCR-mimetic antibodies to make an off-the-shelf T-cell engager and other immunotherapies. According to the company, its T-Bolt molecules can be adopted across a broad range of cancers.

One More Thing: Scientific Advisory Board member Paul Workman is a precision cancer treatment pioneer, having developed the concept of the Pharmacological Audit Trail for biomarker-led drug discovery and development.

Notable: Initial Therapeutics is another startup that bills itself on attempting to drug undruggable targets, in this case using selective termination of protein synthesis, or STOPS, to discover therapeutics.

One More Thing: Co-founder and UCSF professor Kevan Shokat developed a successful approach to drugging a protein produced by the mutated KRAS gene, an achievement for which he was honored with two prestigious awards in 2023.

Notable: One of the more unique companies on this list, Aether Bio is using generative AI and automation to find novel biocatalysts. With its molecular assembler platform, Aether intends to create enhanced products across the healthcare, home electronics and automotive industries.

In November 2021, the Biden Administration signaled that in line with its strategic vision for Medicaid, waivers can foster expanded coverage; improved access, quality, and equity; and value-based care and innovation. Prior to the November 2021 enumeration of these strategic Medicaid priorities, in a January 2021 executive order President Biden identified strengthening Medicaid and increasing health care access as key administrative priorities. The executive order directed relevant agencies to review waiver policies that may reduce coverage under or otherwise undermine Medicaid.

CMS decisions on a number of pending waiver requests will inform how the Biden Administration may use waivers to advance stated priorities (Figure 1). In the year since President Biden took office, many states have requested targeted eligibility expansions that would increase coverage and access to care for certain populations, including justice-involved individuals. Though no states have received waiver approval to provide services prior to release from incarceration, CMS recently expressed support for pre-release services in correspondence with California. Recent pending waivers also propose to address health-related social needs and behavioral health needs, areas identified as key priorities by both CMS and states. As federal Medicaid rules prohibit expenditures for most non-medical services, it remains to be seen whether and how the Biden Administration may use demonstration waivers to encourage states to address enrollee social determinants of health.

Last year, towards the end of August 2020, I published a Week On The Wrist story about the Seiko Prospex SPB143. On paper, the SPB143 looked like an ideal blend of features, proportion, and price that offered a distinct step up from an SKX007 or an SRP777 without going deeper into the four-figure range for something like an SLA017. And in the metal, it delivered.

How is the timekeeping?

Good, but not great. Basically just what you would expect from a stock 6R15 movement. In preparing for this post I did a couple days of time checks and my example loses about 4-5 seconds a day (dial-up) but tends to become somewhat more erratic on the wrist (-3 one day, +7 the next, maybe more). Please note that I did not use any legit accuracy testing equipment and that my results are anecdotal.

I checked with Seiko and they confirmed that the addition, both to the SPB143 and several other models, was to catch up with the spec requiring a lume plot for each 5-minute indication on the dial. You can even see the mini-plot on the previously mentioned (and later to be released) SPB213, shown above.

Many Rolex watches have a clasp code located inside the clasp hinge. This code is based on the month and year the clasp was manufactured. After inspecting the clasp you will see 1 or 2 letters followed by a number. The letter corresponds with a year and the number signifies a month. For instance, per the table below, we see that a bracelet stamped G4 was manufactured in April 1982. A service replacement bracelet would have an additional "S" stamped along with the year.

The table below lists all the 3 digit country codes for Rolex watches. This country code can be found in the upper left hand corner on the Rolex Guaranty Certificate. There is no country code for the USA and most watches older than 1980 will NOT have a country code.

The Rolex serial numbers are found between the lugs on the side of the case at the 6 o'clock side, behind the bracelet. This 4-8 digit number is engraved by Rolex on every watch and it can be used to determine its production date. Beginning in 2005, the Company started to also engrave the serial number on the inside flange (or "rehaut" as it's called in French) between the dial and the crystal. Starting in 2008, the Company began to only engrave the numbers on the rehaut. We provide this verified database chart for those folks looking for an answer to an often asked question, "where or how do I find the Rolex serial numbers on my watch."

While there is no "Official" Rolex Serial numbers database list from the Rolex Factory that shows dates of production, this chart below lists all the serial numbers gathered by proven authorities over the years. See the list below by production year to learn the year your watch was made. If you decide to sell a Rolex, check out our official price list before doing so. We've also added a serial numbers look-up table for Tudor watches below. These charts will be frequently updated to reflect any changes in the numbering system for future years. For more information on how these numbers work, click here - Wikipedia

c80f0f1006